Показаны сообщения с ярлыком forecast. Показать все сообщения
Показаны сообщения с ярлыком forecast. Показать все сообщения

пятница, 29 декабря 2023 г.

Marketers' Business and Budget Expectations for 2024

 Most marketers expect business will be better in 2024 compared with 2023, according to recent research from WARC.

The Voice of the Marketer 2024 report was based on WARC's annual survey of more than 1,400 marketers worldwide.

Some 61% of marketers surveyed expect that business will improve in 2024, up from 51% who said the same in last year's survey.


Some 41% of marketers believe that their marketing budgets will increase in 2024.

The top channels marketers expect to increase spend on next year are YouTube and TikTok. The top channel marketers expect to decrease spend on in 2024 is X/Twitter.


Some 39% of marketers say measurement is one of their top concerns for 2024.

More than half (54%) of marketers say brand metrics (e.g., awareness, consideration, purchase intent) are among the measures of effectiveness that have the greatest impact on their marketing strategy.


About the research: The Voice of the Marketer 2024 report was based on WARC's annual survey of more than 1,400 marketers worldwide.


https://www.marketingprofs.com/

среда, 28 сентября 2022 г.

Quantitative Methods

 


Summary: This is my ultimate notes summary for the subject quantitative methods (statistic). It includes notes on the essentials of data collections, forecasting methods (moving average, weighted moving average, exponential smoothing, linear trend analysis, seasonality analysis, errors, etc.) and you learn about how to calculate a regression line and read excel output. The summary also includes the conjoint analysis, part-worth calculation and cluster analysis.

















https://bit.ly/3RNq3d3

понедельник, 19 февраля 2018 г.

Top 31 Most Promising Drugs 2018


All the most promising drugs approved by FDA in 2017 and their future potential

In 2017, the Center for Drug Evaluation and Research (CDER) of FDA approved 46 novel drugs. This represents a significant growth compared to the 22 new novel medications approved in 2016. The positive trend of approval in 2017 signifies that we are still going to see many novel drug launches in 2018.

Here is the list of the most promising drugs approved in 2017 that have been recently launched or will be launched in 2018:


Sources: Annual reports, SEC filings, Press releases, Company websites, U.S. FDA website

https://igeahub.com/


пятница, 6 октября 2017 г.

The Flare and Focus of Successful Futurists


The ability to plausibly forecast the future requires alternating between broad and narrow ways of thinking.



Futurists are skilled at listening to and interpreting signals, which are harbingers of what’s to come. They look for early patterns — pretrends, if you will — as the scattered points on the fringe converge and begin moving toward the mainstream. The fringe is that place where hackers are experimenting, academics are testing their ideas, technologists are building new prototypes, and so on. Futurists know most patterns will come to nothing, so they watch and wait and test the patterns to find those few that will evolve into genuine trends. Each trend is a looking glass into the future, a way to see over time’s horizon. This is the art of forecasting the future: simultaneously recognizing patterns in the present and thinking about how those changes will impact the future so that you can be actively engaged in building what happens next — or at least be less surprised by what others develop. Futures forecasting is a learnable skill, and a process any organization can master.
Joseph Voros, a theoretical physicist and senior lecturer in strategic foresight at Swinburne University of Technology in Melbourne, Australia, offers my favorite explanation of futures forecasting, saying it informs strategy making by enhancing the “context within which strategy is developed, planned, and executed.”1 The advantage of forecasting the future in this way is obvious: Organizations that can see trends early can better prepare to take advantage of them. They can also help shape the broader context, with an understanding of how developments in seemingly unconnected industries will affect them. Most organizations that track emerging trends are adept at conversing and collaborating with those in other fields to plan ahead.
Although futures studies is an established academic discipline, few companies employ futurists. That’s starting to change as more leaders become familiar with the work futurists do. Accenture, Ford, Google, IBM, Intel, Samsung, and UNESCO all have had futurists on staff, and their work is quite different from what happens within the traditional research and development (R&D) function.
The futurists at these organizations know that their tools are best used within a group — and that the group’s composition matters tremendously to the outcomes they produce. Here’s why. Within every organization are people whose dominant characteristic is either creativity or logic. If you’ve been on a team that included both groups and didn’t have a great facilitator during your meetings, your team probably clashed. If it was an important project and there were strong personalities representing each side, the creative people felt as though their contributions were being discounted, while the logical thinkers — whose natural talents lie in managing processes, projecting budgets, or mitigating risk — felt undervalued because they weren’t coming up with bold new ideas. Your team undoubtedly had a difficult time staying on track, or worse, you might have spent hours meeting about how to have your next meeting. I call this the “duality dilemma.”
The duality dilemma is responsible for a lack of forward thinking at many organizations. It contributed to the decline of BlackBerry Ltd.’s smartphone business; the company (formerly known as Research in Motion Ltd.) never had an executable plan to remake the phone’s form factor and operating system in the age of the iPhone. Right-brained creatives wanted to make serious changes to the phone, while left-brained process thinkers were fixated on risk and maintaining BlackBerry’s customer base.2 The future of the business hinged on the company’s ability to bring both forces together to forecast trends and plan for the future.
BlackBerry’s experience suggests that forecasting the future of a product, company, or industry should neither be relegated to inventive visionaries nor mapped entirely by left-brain thinkers. Futures forecasting is meant to unite opposing forces, harnessing both wild imagination and pragmatism.

Turning a Dilemma Into a Dynamic

Overcoming the duality dilemma — and getting full use of both your creative- and logic-oriented team members — in order to track emerging trends and forecast the future is possible. But counterintuitively, it’s a matter of highlighting — rather than discouraging or downplaying — the strengths of each side. Stanford University’s Hasso Plattner Institute of Design (also known as the d.school) teaches a brainstorming technique that addresses the duality dilemma and illuminates how an organization can harness both strengths in equal measure by alternately broadening (“flaring”) and narrowing (“focusing”) its thinking.3
When a team is flaring, it is finding inspiration, making lists of ideas, mapping out new possibilities, getting feedback, and thinking big. When it is focusing, those ideas must be investigated, vetted, and decided upon. Flaring asks questions such as: What if? Who could it be? Why might this matter? What might be the implications of our actions? Focusing asks: Which option is best? What is our next action? How do we move forward?
The forecasting method I have developed — one, of course, influenced by other futurists but different in analysis and scope — is a six-step process that I have refined during the past decade as part of my work at the Future Today Institute. The first four steps involve finding a trend, while the last two steps inform what action you should then take. (See “A Six-Step Forecasting Methodology.”)

пятница, 1 июля 2016 г.

EvaluatePharma World Preview 2015 Outlook to 2020

The eighth edition of the EvaluatePharma® World Preview 2015, Outlook to 2020 report brings together many of our analyses to provide a top level insight, from the world's financial market, into the expected performance of the industry between now and 2020.
If there was any doubt that the pharmaceutical industry is entering a period of sustained growth it should be put to rest by this report showing prescription drug sales are set to advance at almost 5% a year until 2020. 
Watch Anthony Raeside, Head of Research at Evaluate, discussing World Preview 2015 at BIO 2015. 

Key highlights in EvaluatePharma® World Preview 2015, Outlook to 2020 include:
  • Worldwide prescription drug sales are expected to reach almost $1 trillion by 2020 (CAGR: 4.8% between 2014 and 2020)
  • Key prescription drug sales jumped 4.9% in 2014, driven by an 8.9% surge in USA sales; Europe returns to growth at 2.4%; Japan slumps 2.6% in yen
  • Industry's R&D pipeline valued at $493bn; Gilead's potential new combination hepatitis C product most valuable
  • Humira remained the top-selling product in 2014 with sales of $13bn; Sovaldi debuts at number two with sales of $10bn
  • A record number of new drugs were approved by the US FDA in 2014; sales potential increases by 45%
  • AbbVie's Humira continues to account for over 25% of the anti-rheumatic market in 2020
  • Gilead continues to dominate the anti-viral segment in 2020 capturing over 50% of the entire market

четверг, 31 марта 2016 г.

Sensitivity Analysis

Slide2s



You often have to forecast business results or analyze investment proposals by making assumptions on a number of parameters. The key assumptions may relate to revenue (price, volume, mix), costs (fixed vs. variable, material vs. labor, etc.) or other variables (capital invested, etc.). A presentation on such a business outlook should always include a sensitivity analysis and a discussion of potential scenarios. The way I suggest to do this:

(1) Identify the key metric used to evaluate the business or the investment proposal (in the example below: Return on Sales).

(2) Show on one slide which assumptions potentially have the biggest impact on this metric.




(3) Take the two or three most critical variables, and calculate how the key business metric would look like of you change the base assumption to an optimistic scenario vs. a pessimistic scenario.


If you do this only for two key variable, it’s quite easy to show it graphically – a simple 3×3 matrix (or you can even do a 5×5 matrix with more gradual scenarios). If you do it for three key variables, you will have to work witha tree structure and multiple matrices – as shown above. You can also highlight in color which scenarios fulfull a certain threshhold. For example, if your company has a minimum requirement of a 5% Return on Sale, all boxes where the ROS is below 5% could be colored in red.

вторник, 15 декабря 2015 г.

Top 10 Healthcare Predictions For 2016



Reenita Das

As 2015 comes to a close, Frost & Sullivan experts and thought leaders gather together to predict the top 10 trends to expect during the coming year.
  1. Next generation wearables hit a $6 billion market
The new generation of “medical” or “clinical wearables” is going to be equipped with more sophisticated sensing, capture and analytical functionalities, thus making the clinical utility of those devices more actionable. Currently, sales of healthcare wearables primarily involve monitoring technologies like those developed by Vital Connect and Proteus Digital Health; moving forward, technologies like the Quell from Neurometrix that provides therapeutic support will continue to gain traction.
Expect healthcare and consumer technology companies alike to be highly active in exploring strategic acquisitions of early stage wearable companies.
Frost & Sullivan’s recent study on consumer behavior to digital health shows approximately 24% of consumers currently use mobile apps to track health and wellness, 16% use wearable sensors and 29% use electronic personal health records. This trend is expected to continue as 47% of consumers would consider using wearables in the near future.
Reenita Forbes Blog - Healthcare Predictions for 2016 image 1
  1. Retail care goes mainstream with 35% expansion of in-store clinic footprint
2015 witnessed retailers allocating a great deal of investment toward expanding their clinical footprint, acquiring new tools and forming unique partnerships with healthcare companies. Consequently, 2016 should see the efforts of those machinations as retailers begin to fully execute their strategies for becoming the front line of primary care services.

  1. New Development Bank (NDB) invests heavily in healthcare, changing dynamics in many countries
With a total capital of $100 billion, the NDB was formed as an alternative to other world banking organizations dominated by American and European stakeholders. Formerly the BRICS (Brazil, Russia, India, China, South Africa) Bank, the NDB is focused on improving the lives of citizens in developing nations. Its key initiatives include significant infrastructure investment in healthcare and wellness services for underserved populations.

  1. Rapid Expansion of Private Insurance in India finally unlocks untapped market
Through March 2014, only 17% of Indians were covered by health insurance, resulting in a high (more than 75%) out-of-pocket burden for care. The new government is prioritizing healthcare, through the National Health Assurance Mission, which will provide free drugs and diagnostic services as well as help individuals gain access to low-cost insurance schemes.

  1. Population Health opportunity drives over $50 billion in healthcare M&A
Long term corporate strategy aligned with opportunities tied to population health management is expected to drive decision-making tied to corporate restructuring, M&A, spin-offs, R&D spending and venture arm investments. Industry participants must evolve or risk obsolescence in a new healthcare industry paradigm where compensation is tied to outcomes.
The requirements for population health tools are forcing companies to consider their acquisition strategies differently, leading to more transactions involving companies in adjacent or complimentary markets.

  1. Less expensive and faster point of care (POC) testing enables new diagnostic care models
Commercialization of new POC test platforms with capabilities such as molecular POC, connectivity features, biosensors and microfluidics is able to drastically improve turnaround times (5 to15 minutes) and allow for testing services to be performed in settings previously not feasible.

  1. Free preventative care services available to over 90% in the U.S.
To mitigate the cost and care burden of late-stage chronic diseases, everyone from payers, employers, and the government will be offering a wide range of technology and wellness enabled preventative services. With access now available, it remains to be seen how engaged consumers will be in leveraging those services.
  1. Healthcare IoT solutions spur $10 billion in venture capital investments for start-ups
 The startup environment in healthcare is being reinvigorated by a wide spectrum of early stage companies looking to bring their IoT expertise honed in other industries to healthcare. With a focus on “disruptive” business models, these companies are looking to help tear down outmoded forms of care delivery and deploy approaches  optimizing new tools and technologies.
  1. Hospitals investing heavily in overhauling and retooling outdated facilities to avoid closure trends
 Ongoing trends of hospital closures and consolidations are forcing hospitals to rethink everything from hospital layout to resource utilization. Initiatives like the $1.3 billion overhaul of Dallas’s Parkland Hospital are happening around the country, as those institutions seek to adapt to new forms of care delivery that emphasize efficiency and patient satisfaction.
  1. The global regenerative medicine market to reach $30 billion in 2016
Pharmaco will see the regenerative market as its trump card as the business is expected to see growth rates of 22.4% from 2015. With growing investments in this area, favorable legislative policies and an increasing number of cell therapy marketed products this business will witness new competitors vying for a slot.
Image 3
With these changes and disruptions looming ahead, it is essential for companies to start asking critical questions, such as whether there is a data and analytics strategy and platform in place. How will the company monetize population health management to align with value based care models in the future? How to start the process of building a patient engagement platform that goes across the care continuum and look at it from the patient or consumer’s point of view, not a company perspective? It is critical that as data science replaces the block buster drug or device as the king or queen of the healthcare world, companies start taking some risks and build a culture of collaboration to succeed in 2016.